237 related articles for article (PubMed ID: 25562725)
1. CYP2D6 phenotype-specific codeine population pharmacokinetics.
Linares OA; Fudin J; Schiesser WE; Daly Linares AL; Boston RC
J Pain Palliat Care Pharmacother; 2015 Mar; 29(1):4-15. PubMed ID: 25562725
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
3. The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects.
Wu X; Yuan L; Zuo J; Lv J; Guo T
Eur J Clin Pharmacol; 2014 Jan; 70(1):57-63. PubMed ID: 24077935
[TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.
Crews KR; Gaedigk A; Dunnenberger HM; Klein TE; Shen DD; Callaghan JT; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2012 Feb; 91(2):321-6. PubMed ID: 22205192
[TBL] [Abstract][Full Text] [Related]
5. A Compartmental Analysis for Morphine and Its Metabolites in Young Children After a Single Oral Dose.
Velez de Mendizabal N; Jimenez-Mendez R; Cooke E; Montgomery CJ; Dawes J; Rieder MJ; Aleksa K; Koren G; Jacobo-Cabral CO; Gonzalez-Ramirez R; Castañeda-Hernandez G; Carleton BC
Clin Pharmacokinet; 2015 Oct; 54(10):1083-90. PubMed ID: 25773480
[TBL] [Abstract][Full Text] [Related]
6. Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure.
Badaoui S; Hopkins AM; Rodrigues AD; Miners JO; Sorich MJ; Rowland A
AAPS J; 2021 Jan; 23(1):15. PubMed ID: 33404848
[TBL] [Abstract][Full Text] [Related]
7. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype.
Mikus G; Trausch B; Rodewald C; Hofmann U; Richter K; Gramatté T; Eichelbaum M
Clin Pharmacol Ther; 1997 Apr; 61(4):459-66. PubMed ID: 9129563
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.
Caraco Y; Sheller J; Wood AJ
J Pharmacol Exp Ther; 1997 Apr; 281(1):330-6. PubMed ID: 9103514
[TBL] [Abstract][Full Text] [Related]
9. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.
Linares OA; Daly D; Linares AD; Stefanovski D; Boston RC
Pain Med; 2014 May; 15(5):791-806. PubMed ID: 24517173
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin?
He YJ; Brockmöller J; Schmidt H; Roots I; Kirchheiner J
J Anal Toxicol; 2008 Mar; 32(2):178-82. PubMed ID: 18334103
[TBL] [Abstract][Full Text] [Related]
11. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation.
Eckhardt K; Li S; Ammon S; Schänzle G; Mikus G; Eichelbaum M
Pain; 1998 May; 76(1-2):27-33. PubMed ID: 9696456
[TBL] [Abstract][Full Text] [Related]
12. Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study.
Willmann S; Edginton AN; Coboeken K; Ahr G; Lippert J
Clin Pharmacol Ther; 2009 Dec; 86(6):634-43. PubMed ID: 19710640
[TBL] [Abstract][Full Text] [Related]
13. Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites.
Lötsch J; Skarke C; Schmidt H; Rohrbacher M; Hofmann U; Schwab M; Geisslinger G
Clin Pharmacol Ther; 2006 Jan; 79(1):35-48. PubMed ID: 16413240
[TBL] [Abstract][Full Text] [Related]
14. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
Crews KR; Gaedigk A; Dunnenberger HM; Leeder JS; Klein TE; Caudle KE; Haidar CE; Shen DD; Callaghan JT; Sadhasivam S; Prows CA; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2014 Apr; 95(4):376-82. PubMed ID: 24458010
[TBL] [Abstract][Full Text] [Related]
15. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
VanderVaart S; Berger H; Sistonen J; Madadi P; Matok I; Gijsen VM; de Wildt SN; Taddio A; Ross CJ; Carleton BC; Hayden MR; Koren G
Ther Drug Monit; 2011 Aug; 33(4):425-32. PubMed ID: 21743374
[TBL] [Abstract][Full Text] [Related]
16. The pharmacogenetics of codeine hypoalgesia.
Sindrup SH; Brøsen K
Pharmacogenetics; 1995 Dec; 5(6):335-46. PubMed ID: 8845855
[TBL] [Abstract][Full Text] [Related]
17. Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease.
Molanaei H; Carrero JJ; Heimbürger O; Nordfors L; Lindholm B; Stenvinkel P; Odar-Cederlöf I; Bertilsson L
Eur J Clin Pharmacol; 2010 Mar; 66(3):269-73. PubMed ID: 19940985
[TBL] [Abstract][Full Text] [Related]
18. Codeine in post-operative pain. Study of the influence of sparteine phenotype and serum concentrations of morphine and morphine-6-glucuronide.
Poulsen L; Riishede L; Brøsen K; Clemensen S; Sindrup SH
Eur J Clin Pharmacol; 1998 Aug; 54(6):451-4. PubMed ID: 9776433
[TBL] [Abstract][Full Text] [Related]
19. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects.
Caraco Y; Sheller J; Wood AJ
J Pharmacol Exp Ther; 1999 Jul; 290(1):413-22. PubMed ID: 10381807
[TBL] [Abstract][Full Text] [Related]
20. Individualized Hydrocodone Therapy Based on Phenotype, Pharmacogenetics, and Pharmacokinetic Dosing.
Linares OA; Fudin J; Daly AL; Boston RC
Clin J Pain; 2015 Dec; 31(12):1026-35. PubMed ID: 25621429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
